6.6
Agonistas adrenérgicos: Agentes de Ação Indireta
Os agonistas adrenérgicos de ação indireta potencializam os efeitos das catecolaminas endógenas por diferentes mecanismos, sem se ligarem diretamente…
Os agonistas adrenérgicos de ação indireta aumentam o efeito das catecolaminas endógenas por meio de mecanismos variados.
Agonistas como anfetamina e tiramina são chamados de "deslocadores", pois induzem a liberação de catecolaminas esgotando seus estoques da vesícula sináptica.
Eles se assemelham à noradrenalina, mas não possuem uma porção catecol. Devido a essa semelhança, eles são ativamente transportados para os vasos sinápticos e, eventualmente, substituem a noradrenalina.
A noradrenalina citosólica é então trocada por outra molécula deslocadora e liberada para atuar nos adrenoceptores pós-sinápticos.
Outro mecanismo envolve a inibição da recaptação de catecolaminas. A cocaína bloqueia o transportador envolvido na recaptação de catecolaminas, potencializando assim a ação simpatomimética.
Além disso, a selegilina - um inibidor da MAO e a entacapona - um inibidor da COMT, são simpatomiméticos de ação indireta, pois impedem o metabolismo e a subsequente excreção de catecolaminas circulantes.
Agonistas de ação indireta, como cocaína e anfetamina, são frequentemente abusados devido aos seus efeitos centrais, como euforia resultante da liberação de dopamina e serotonina.
View the full transcript and gain access to JoVE Core videos
Q1: How do displacer drugs like amphetamine and tyramine work as indirect-acting agonists?
Displacers resemble noradrenaline but lack a catechol moiety, allowing active transport into synaptic vesicles. Once inside, they replace stored noradrenaline, which is then released to act on postsynaptic adrenoceptors. This mechanism enhances sympathomimetic effects without directly binding to receptors. Amphetamine and tyramine exemplify this displacement strategy.
Q2: What is the mechanism by which cocaine acts as an indirect-acting sympathomimetic?
Cocaine blocks the transporter responsible for catecholamine reuptake, preventing noradrenaline and dopamine from being removed from the synaptic cleft. This potentiates sympathomimetic action by prolonging neurotransmitter availability at adrenoceptors. As a local anesthetic with reuptake-inhibiting properties, cocaine produces both peripheral and central nervous system effects.
Q3: How do MAO inhibitors and COMT inhibitors enhance catecholamine effects?
MAO inhibitors like selegiline and COMT inhibitors like entacapone prevent the breakdown and excretion of circulating catecholamines. By blocking these metabolic pathways, these enzyme inhibitors increase catecholamine concentration and duration of action, indirectly potentiating sympathomimetic responses without directly activating adrenoceptors.
Q4: Why do amphetamine and cocaine have abuse potential despite their pharmacological differences?
Both amphetamine and cocaine stimulate central nervous system effects, particularly dopamine and serotonin release, producing euphoria and reward sensations. Although they use different mechanisms—displacement versus reuptake inhibition—both drugs enhance monoamine availability in the brain, driving their addictive potential and abuse liability.
Q5: What structural feature distinguishes displacer agonists from direct-acting adrenergic agonists?
Displacer agonists like amphetamine and tyramine lack a catechol moiety present in noradrenaline and direct-acting agents. This structural difference enables their active transport into synaptic vesicles, improves oral bioavailability, and enhances central nervous system penetration. The absence of the catechol group is essential to their displacement mechanism.
Q6: How does tyramine in fermented foods interact with MAO inhibitor medications?
Tyramine, a displacer agonist found in fermented foods, mimics sympathetic responses by releasing stored catecholamines. When individuals take MAO inhibitors, tyramine metabolism is blocked, causing excessive accumulation and potentiation of sympathomimetic effects. This interaction can produce dangerous hypertensive responses, making dietary tyramine restriction important during MAO inhibitor therapy.
Q7: What distinguishes indirect-acting agonists from direct-acting agents in their mechanism of action?
Indirect-acting agonists enhance endogenous catecholamine effects through displacement, reuptake inhibition, or enzyme inhibition rather than directly binding to adrenoceptors. Direct-acting agents bind directly to adrenoceptors to produce their effects. Indirect agents potentiate existing neurotransmitter activity, while direct agents independently activate receptors.